Integration of bulk and single-cell RNA-seq reveals prognostic gene signatures in patients with bladder cancer treated with immune checkpoint inhibitors.

ABSTRACT: Immune checkpoint inhibitors have significantly advanced research in oncology and are used to successfully treat patients with bladder cancer (BC). However, as the benefits of programmed death-1/ programmed death-ligand-1 blockade immunotherapy do not extend to all patients with BC, biomarkers are required to improve prognostic stratification. This study aims to identify reliable biomarkers to enhance the prediction of treatment outcomes. Bulk RNA expression data from a BC cohort (GSE176307) receiving ICI and single-cell sequencing data from patients with BC (GSE135337) were collected. We identified differentially expressed genes (DEGs) within cells that were associated with favorable survival outcomes and developed a predictive bladder cancer gene signature (BC-GS). Subsequently, we perfo

SUBMITTER: Cho M 

PROVIDER: S-EPMC11663206 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature